IPO Class of 2015: A Top 25 Ranking

Today the markets staged a big advance, led by the Nasdaq's 2.46% rally. Nevertheless, we remain in a market correction. The IPO market has quieted down in the aftermath, with nothing expected to price in the next few weeks. In the meantime, we screened the IPO Class of 2015, and ranked them by their performance. Here are the Top 25, as of today's close:

1. Tantech Holdings (TANH) up 623% since March 24 IPO date
2. The Global Blood (GBT) up 160% since August 11 IPO date
3. Seres Therapeutics (MCRB) up 133% since June 25 IPO date
4. Inotek Pharmaceuticals (ITEK) up 132% since Feb 18 IPO
5. Shake Shack (SHAK) up 131% since Jan 29 IPO

6. Zynerba Pharma (ZYNE) up 115% since Aug 4 IPO
7. Spark Therapeutics (ONCE) up 89% since Jan 30 IPO
8. Kempharm Inc (KMPH) up 82% since Apr 15 IPO
9. Pronai Therapeutic (DNAI) up 79% since July 15 IPO
10. Neos Therapeuritc (NEOS) up 77% since July 23 IPO

11. Chiasma Inc (CHMA) up 77% since July 15 IPO
12. Fitbit Inc (FIT) up since June 17 IPO
13. Glaukos Corp (GKOS) up 66% since June 24 IPO
14. Blueprint Medical (BPMC) up 58% since April 29 IPO
15. Kearny Financial (KRNY) up 57% since May 14 IPO

16. Wingstop (WING) up 44% since June 11 IPO
17. Solaredge Technology (SEDG) up 41% since March 26 IPO
18. Aimmune Therapeutic (AIMT) up 39% since Aug 5 IPO
19. Black Knight (BKFS) up 37% since May 19 IPO
20. Press Ganey (PGND) up 33% since May 20 IPO

21. Appfolio (APPF) up 31% since June 25 IPO
22. Summit Materials (SUM) up 30% since March 11 IPO
23. Rapid 7 Inc (RPD) up 30% since July 16 IPO
24. Entellus Medical (ENTL) up 29% since Jan 28 IPO
25. Collegium Pharma (COLL) up 26% since May 6 IPO

Once again we point out the overwhelming presence of healthcare companies on this list. Biotechs and pharmaceuticals have dominated the IPO market of the recent bull cycle. Of particular interest is the performance of GBT, ZYNE, DNAI and NEOS, which have all managed huge returns in the past month in spite of the overall market correction.

We have provided links to the two companies we've recently published research on Seeking Alpha, AIMT and RPD.

Should the market correction resolve itself in the coming weeks, we will post any actions we take. To date, our portfolio is in all cash. Readers of IBD will note the occurrence of a follow-through day to change the market from correction to a bull uptrend.